Hygieia and TempraMed Announce Innovative Partnership

LIVONIA, Mich. - Jan. 17, 2024 - PRLog -- In a groundbreaking move, TempraMed, a leader in advanced temperature-based pharmaceutical storage solutions, and Hygieia, a pioneer in autonomous insulin management, have announced a strategic partnership. This relationship brings the cutting-edge technologies of both companies to a much broader audience, helping more people simplify and more effectively manage their diabetes care.

TempraMed has been at the forefront of technological innovation with its flagship product, the VIVI Cap. This lightweight, reusable insulin pen cap represents a significant leap forward in diabetes care. VIVI Cap is changing how people manage their diabetes medication.

Hygieia's d-Nav® technology is the first FDA-cleared AI-driven system that autonomously adjusts insulin doses based on the unique needs of its user. This enables more frequent and optimal dose adjustments to better manage glucose levels. In addition to the app which handles dosing, d-Nav users are supported by a team of expert clinicians who review patient data and stay in frequent communication. The program has shown patient results, with studies indicating significant reductions in A1c for patients in as early as three months.

Uniting in a dynamic partnership, Hygieia and TempraMed are set to harness their collective strengths, embarking on a mission to revolutionize diabetes management. This collaboration is designed to empower individuals with diabetes, enhancing their health and transforming their daily lives with ease and efficiency.

We are incredibly excited to partner with Hygieia, a collaboration that marks a new chapter in diabetes management," stated Ron Nagar, CEO of TempraMed, "This partnership represents more than just a cooperation between technologies; it's a fusion of visions, empowering our customers with an array of transformative tools designed to simplify and enhance their daily lives. We recognize the distinct challenges faced by individuals with diabetes and are confident that this alliance will significantly elevate their ability to manage their condition, safeguard their insulin, and ultimately, elevate their overall well-being."

VIVI Cap, please visit http://www.tempramed.com

Hygieia, please visit https://d-nav.com/

TempraMed is at the forefront of creating and delivering groundbreaking personal storage solutions for injectable medications. Our mission is to address the long-standing gap in the market for individuals who use injectable medications and seek to embrace a lifestyle marked by greater spontaneity, convenience, and safety. TempraMed's first launched product VIVI Cap insulin temperature shield pen cap, is scientifically validated, VIVI Cap provides 24/7/365 years of temperature protection for insulin without the need for any user intervention.

Hygieia is the developer of d-Nav®, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav's AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body's changing insulin needs. Studies have shown that nearly 90 percent of people using d-Nav report lower A1C in just three months* without increasing the risk for hypoglycaemia**. The d-Nav Insulin Management Program has been peer-reviewed with studies published in leading medical journals.

* John E Schneider et al. Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses. J Health Econ Outcomes Res. 2018 Feb 20;6(1):53-62. https://jheor.org/article/9783

** Richard M Bergenstal et al. Automated insulin dosing guidance to optimize insulin management in patients with type 2 diabetes: a multicenter, randomized controlled trial. Lancet 2019 Mar 16;393(10176):1138-1148. https://pubmed.ncbi.nlm.nih.gov/30808512/d-Nav is prescribed by medical professionals and is accessible via Hygieia's clinic in Michigan or through their endocrinologist clinical partners in select states.